Wanchun Pharmaceutical's U.S. listing application for pranabulin was granted priority review by FDA

Article source: Medical Rubik's Cube Info

On June 1, Wanchun Medicine announced that its core product "Punablin Concentrate Solution for Injection" for use in chemotherapy-induced severe neutropenia (CIN) for new drug listing applications (NDA) has been officially accepted by the US FDA , And obtained the priority review qualification granted by the FDA.

Regardless of whether it is first-line or post-line treatment, chemotherapy is still an indispensable part of the current standard treatment plan for cancer.

Pranabrin is the First-In-Class Guanine Nucleotide Exchange Factor (GEF-H1) activator independently developed by Wanchun Pharmaceutical.

On November 16, Wanchun Medicine announced the international multi-center phase III study PROTECTIVE- of prenabrin combined with pegfilgrastim vs.

What’s more noteworthy is that as the world’s first immune small molecule drug that stimulates the maturation of dendritic cells, enhances antigen presentation, and activates T cells, punabulin is expected to become another blockbuster after PD-1/L1.

Note: The original text has been deleted